Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,941 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.
Suzuki H, Iwamoto H, Seki T, Nakamura T, Masuda A, Sakaue T, Tanaka T, Imamura Y, Niizeki T, Nakano M, Shimose S, Shirono T, Noda Y, Kamachi N, Sakai M, Morita K, Nakayama M, Yoshizumi T, Kuromatsu R, Yano H, Cao Y, Koga H, Torimura T. Suzuki H, et al. Among authors: tanaka t. Cancer Commun (Lond). 2023 Apr;43(4):415-434. doi: 10.1002/cac2.12411. Epub 2023 Feb 24. Cancer Commun (Lond). 2023. PMID: 36825684 Free PMC article.
Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer.
Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, Wada F, Masuda A, Tanaka T, Fukahori M, Ushijima T, Mihara Y, Naitou Y, Okabe Y, Kakuma T, Ohta K, Nakamura KI, Torimura T. Sakaue T, et al. Among authors: tanaka t. Med Mol Morphol. 2019 Dec;52(4):198-208. doi: 10.1007/s00795-019-00218-5. Epub 2019 Feb 25. Med Mol Morphol. 2019. PMID: 30805710 Clinical Trial.
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events.
Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Sakai M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T. Iwamoto H, et al. Among authors: tanaka t. Cancers (Basel). 2020 Apr 19;12(4):1010. doi: 10.3390/cancers12041010. Cancers (Basel). 2020. PMID: 32325921 Free PMC article.
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments.
Suzuki H, Iwamoto H, Nakano M, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Kuromatsu R, Niizeki T, Okamura S, Shimose S, Shirono T, Noda Y, Kamachi N, Yano H, Kawaguchi A, Koga H, Torimura T. Suzuki H, et al. Among authors: tanaka t. Transl Oncol. 2021 Nov;14(11):101201. doi: 10.1016/j.tranon.2021.101201. Epub 2021 Aug 11. Transl Oncol. 2021. PMID: 34388691 Free PMC article.
16,941 results
You have reached the last available page of results. Please see the User Guide for more information.